Jacobio Pharma shared a post on LinkedIn:
“Jacobio Pharma Announces Exclusive Global Licensing Agreement with AstraZeneca for Pan-KRAS Inhibitor JAB-23E73
We are pleased to announce that Jacobio Pharma has entered into an exclusive global license agreement with AstraZeneca for our innovative Pan-KRAS inhibitor JAB-23E73.
Under the agreement, AstraZeneca will have exclusive rights to develop and commercialize JAB-23E73 outside China, while both companies will jointly develop and jointly commercialize the therapy in China.
KRAS mutations are among the most common oncogenic drivers, present in approximately 23% of all cancer patients. JAB-23E73 is currently in Phase I clinical trials in the U.S. and China, where early signals of anti-tumor activity have been observed.
This partnership reflects AstraZeneca’s global strength in oncology development and commercialisation, and marks a meaningful milestone in accelerating the worldwide advancement of JAB-23E73.
At Jacobio, we remain committed to advancing innovative medicines for patients worldwide and expanding our leadership across the KRAS pathway and next-generation immuno-oncology platforms.”
Andrea Wang-Gillam, Co-CEO at Jacobio Pharma, shared this post, adding:
“I am very excited about the potential of this partnership, extending beyond accelerating global development to maximizing this program’s scientific and commercial value worldwide.”
More posts about Andrea Wang-Gillam.